The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

ČESKÁ, Katarína, Lukas CESKY, Hana OŠLEJŠKOVÁ a Štefánia AULICKÁ. The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment. Neuropediatrics. STUTTGART: GEORG THIEME VERLAG KG, 2021, roč. 52, č. 01, s. 6-11. ISSN 0174-304X. Dostupné z: https://dx.doi.org/10.1055/s-0040-1718518.

Základní údaje

• Originální název: The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment
• Autoři: ČESKÁ, Katarína (703 Slovensko, domácí), Lukas CESKY (703 Slovensko), Hana OŠLEJŠKOVÁ (203 Česká republika, domácí) a Štefánia AULICKÁ (703 Slovensko, garant, domácí).
• Vydání: Neuropediatrics, STUTTGART, GEORG THIEME VERLAG KG, 2021, 0174-304X.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30103 Neurosciences
• Stát vydavatele: Německo
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Impakt faktor: Impact factor: 1.696
• Kód RIV: RIV/00216224:14110/21:00120783
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.1055/s-0040-1718518
• UT WoS: 000578772900001
• Klíčová slova anglicky: epilepsy; Dravet's syndrome; economic study; costs
• Štítky: 14110320, 14110321, podil, rivok
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

The objective of this study was to estimate the direct cost before and after diagnosis assessment in patients with Dravet's syndrome (DS). The basis of the economic study was to calculate the costs of health care before and after diagnosis of DS. We retrospectively evaluated all SCN1A positive patients with phenotype of DS treated in our hospital. Statistical analyses were performed by IBM SPSS Statistics 24.0 software. After the diagnosis of DS, there was a significant decline of health care costs (-85.6%) an average of Euro29.4 +/- 26.1 monthly per patient. We estimated the monthly costs at Euro204.5 +/- 167 (median: Euro193.9, range: Euro35.5-534.4) per patient before DS diagnosis. The major cost was for hospitalization in neurological department: Euro43.3 +/- 52 (median: Euro21.9, range: Euro9.5-179.4) per patient. Minimal cost per patient per months before DS diagnosis was cost of psychological testing/care and complementary rehabilitation (0.13 and 0.6% of total cost). After DS diagnosis, the major cost was focused on nonhospitalization care of patients (64.8%), minimal (Euro0) for genetic testing and major for outpatient care (18%, mean: Euro5.3, median: Euro7). DS results in essential health care utilization and high financial burden before diagnosis elucidation caused by repeated hospitalization and extensive diagnostics tests of "epileptic encephalopathy of unknown etiology." The results of this study point out that early assessment of the diagnosis leads to significant decrease of the financial costs because of adequate therapeutic management and exclusion of redundant diagnostic testing after elucidation of correct diagnosis.